Cargando…

Genetic Instability and Intratumoral Heterogeneity in Neuroblastoma with MYCN Amplification Plus 11q Deletion

BACKGROUND/AIM: Genetic analysis in neuroblastoma has identified the profound influence of MYCN amplification and 11q deletion in patients’ prognosis. These two features of high-risk neuroblastoma usually occur as mutually exclusive genetic markers, although in rare cases both are present in the sam...

Descripción completa

Detalles Bibliográficos
Autores principales:	Villamón, Eva, Berbegall, Ana P., Piqueras, Marta, Tadeo, Irene, Castel, Victoria, Djos, Anna, Martinsson, Tommy, Navarro, Samuel, Noguera, Rosa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544899/ https://www.ncbi.nlm.nih.gov/pubmed/23341988 http://dx.doi.org/10.1371/journal.pone.0053740

Ejemplares similares

Neuroblastoma after Childhood: Prognostic Relevance of Segmental Chromosome Aberrations, ATRX Protein Status, and Immune Cell Infiltration()
por: Berbegall, Ana P., et al.
Publicado: (2014)

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
por: Berbegall, Ana P., et al.
Publicado: (2018)

MYCN Amplifications and Metabolic Rewiring in Neuroblastoma
por: Pouliou, Marialena, et al.
Publicado: (2023)

Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup
por: Martinez-Monleon, Angela, et al.
Publicado: (2022)

MYCN amplification and ATRX mutations are incompatible in neuroblastoma
por: Zeineldin, Maged, et al.
Publicado: (2020)

Impact of extracellular matrix stiffness on genomic heterogeneity in MYCN-amplified neuroblastoma cell line
por: López-Carrasco, Amparo, et al.
Publicado: (2020)

Aneuploidy in neuroblastoma tumors is not associated with inactivating point mutations in the STAG2 gene
por: Djos, Anna, et al.
Publicado: (2013)

The genetic tumor background is an important determinant for heterogeneous MYCN‐amplified neuroblastoma
por: Bogen, Dominik, et al.
Publicado: (2016)

Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
por: Su, Yan, et al.
Publicado: (2020)

Intratumoral immunosuppression profiles in 11q‐deleted neuroblastomas provide new potential therapeutic targets
por: Coronado, Esther, et al.
Publicado: (2021)

Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort
por: Tadeo, Irene, et al.
Publicado: (2016)

Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification
por: Yue, Zhi-Xia, et al.
Publicado: (2019)

Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification
por: Huang, Can, et al.
Publicado: (2020)

The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma
por: Djos, Anna, et al.
Publicado: (2012)

Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages
por: J Ribelles, Antonio, et al.
Publicado: (2019)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification
por: Defferrari, R, et al.
Publicado: (2015)

Impact of 11q Loss of Heterozygosity Status on the Response of High-Risk Neuroblastoma With MYCN Amplification to Neoadjuvant Chemotherapy
por: Lu, Xian-Ying, et al.
Publicado: (2022)

Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma
por: Keller, Kaylee M., et al.
Publicado: (2022)

MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma
por: Lau, Diana T., et al.
Publicado: (2015)

Effects of preoperative chemotherapy on neuroblastoma with MYCN amplification: a surgeon’s perspective
por: Chui, Chanhon
Publicado: (2020)

Publisher Correction: Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages
por: Juan Ribelles, Antonio, et al.
Publicado: (2020)

CCNB1IP1 prevents ubiquitination‐mediated destabilization of MYCN and potentiates tumourigenesis of MYCN‐amplificated neuroblastoma
por: Zhou, Yang, et al.
Publicado: (2023)

Lymph microvascularization as a prognostic indicator in neuroblastoma
por: Tadeo, Irene, et al.
Publicado: (2018)

Tumor Development, Growth Characteristics and Spectrum of Genetic Aberrations in the TH-MYCN Mouse Model of Neuroblastoma
por: Rasmuson, Agnes, et al.
Publicado: (2012)

Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma
por: Carén, Helena, et al.
Publicado: (2011)

Extracellular Vesicle-Based Method for Detecting MYCN Amplification Status of Pediatric Neuroblastoma
por: Panachan, Jirawan, et al.
Publicado: (2022)

Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group
por: Ambros, Inge M., et al.
Publicado: (2020)

MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma
por: Yue, Zhi‐Xia, et al.
Publicado: (2022)

Imbalance between genomic gain and loss identifies high-risk neuroblastoma patients with worse outcomes
por: Fernández-Blanco, Beatriz, et al.
Publicado: (2020)

Intra-Tumour Genetic Heterogeneity and Prognosis in High-Risk Neuroblastoma
por: López-Carrasco, Amparo, et al.
Publicado: (2021)

MYCN Function in Neuroblastoma Development
por: Otte, Jörg, et al.
Publicado: (2021)

MYCN and Metabolic Reprogramming in Neuroblastoma
por: Bansal, Mohit, et al.
Publicado: (2022)

Metastasis in neuroblastoma: the MYCN question
por: Bhavsar, Swapnil Parashram
Publicado: (2023)

Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures
por: Schoof, Melanie, et al.
Publicado: (2023)

Druggable epigenetic suppression of interferon-induced chemokine expression linked to MYCN amplification in neuroblastoma
por: Seier, Johanna A, et al.
Publicado: (2021)

Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma
por: Yagyu, Shigeki, et al.
Publicado: (2016)

An integrative radiological, histopathological and molecular analysis of pediatric pontine histone-wildtype glioma with MYCN amplification (HGG-MYCN)
por: Tauziède-Espariat, A., et al.
Publicado: (2019)

Multifocal Neuroblastoma and Central Hypoventilation in An Infant with Germline ALK F1174I Mutation
por: Djos, Anna, et al.
Publicado: (2022)

Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment
por: Javanmardi, Niloufar, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ahpk1vod4cnispqa944394lf8p